A Double-Blind, Placebo-Controlled, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of KP-1461 in HIV+ Adults Who Have Failed Two or More Highly Active Antiretroviral Regimens (HAART)
Sponsor study identifier
interventional
40
1 country
9
Study Start
August 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2007
Actual (reported)Study Completion
Not reported
Date not reportedThe primary purpose of the study is to assess the safety and pharmacokinetics of KP-1461 given every 12 hours for 14 days when administered to HIV+ patients who have failed multiple highly active antiretroviral therapy (HAART) regimens. Patients currently on HAART will be required to discontinue all HAART medications for up to 6 weeks after screening eligibility has been determined.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
August 2005
Date type not reportedThis date has not been verified as actual or estimated.
August 9, 2005
Actual (reported)August 11, 2005
Actual (reported)June 2007
Actual (reported)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Bach and Godofsky
Bradenton, Florida, 34205, United States
University of Miami
Miami, Florida, 33146, United States
Triple O Medical Services
West Palm Beach, Florida, 33401, United States
Research Centers of Via Christi
Wichita, Kansas, 67214, United States
Institute of Human Virology, University of Maryland
Baltimore, Maryland, 21201, United States
Dybedal Center for Clinical Research, Kansas City University of Medicine and Biosciences
Kansas City, Missouri, 64106-1453, United States
St. Michael's Medical Center
First Submitted
August 9, 2005
First Posted
August 11, 2005
Study Start
August 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2007
Actual (reported)Safety of and Immune Response to the Experimental Preventive HIV Vaccine, EP HIV-1090, in Healthy, HIV-1 Uninfected Adults
Contact the study team to confirm eligibility.
Newark, New Jersey, 07102, United States
AIDS Community Research Initiative of America
New York, New York, 10018, United States
Greenville Hospital System
Greenville, South Carolina, 29605, United States
Last Updated
January 4, 2008
Record last verified: 2007-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: